Introduction
Gastroschisis is a congenital defect characterized by an opening on the abdominal wall, usually right to the umbilical cord, which affects five in 10,000 live births 1 . The permanent exposure of the bowel loops to the amniotic fluid (AF) changes the intestinal morphology, affecting motility and nutrients absorption 2 .
A proper intestinal length is required for fetal somatic growth. Intestinal anomalies such as gastroschisis may cause intrauterine growth restriction (IUGR) with birth weight less than expected for gestational age 3, 4 . IUGR is frequently seen in fetuses with gastroschisis. Although the causes of IUGR in gastroschisis are still not known, it might be due to the defect itself or to secondary causes like the metabolic response of the bowel in contact with the amniotic fluid 5 . In the rat model of gastroschisis the body weight is decreased and there is an inverse relationship between the length of exposure of the bowel to the amniotic fluid and body weight, so that longer exposure leads to a more decreased body weight in fetuses with gastroschisis 6 .
Inflammatory reactions, as seen in the intestines of fetuses with gastroschisis, can affect fetal hormone production and glucose and amino acid transport by altering fetal differentiation and development. Statistical analysis was performed using ANOVA test with Tukey's post-test. Significant statistical difference was considered when p<0.05.
Results

Morphological
A total 14 pregnant rats with 60 fetuses were studied.
There was no mortality in C and S groups but the mortality rate was 10% (2/22) in fetuses with gastroschisis. We observed a significantly lower body weight and increased intestinal weight and IW/BW ratio in fetuses with gastroschisis compared with controls and shams (p<0.05). The liver weight, as well the LW/ BW, were similar among the three groups (Table 1) . 
Western blotting
Liver. The expression of IRS-1 and IGF-IRB was higher in G (p<0.001) and S (p<0.001) groups compared with C group. Intestine. The expression of IRβ and IRS-1 was lower in G group compared with S (p<0.01) and C (p<0.001) groups.
Intestinal expression of IRS-2 was higher in G and C groups compared with S group, but it was not statistically different.
Expression of non-phosphorylated Ikappa-β was higher in G (p<0.001) and S (p<0.001) groups compared with C group, while the expression of IGF-IRB was higher in G (p<0.001) and C (p<0.001) groups compared with S group (Figure 2) . The IR can also, under special circumstances, phosphorilate in serine residue, which attenuates signaling transmission, causing negative feedback and could result in insulin resistance. This situation can be observed in chronic or acute inflammatory states, when there is release of pro-inflammatory cytokines such as interleukin 1 (IL-1), tumor necrosis factor alfa (TNF-α), and interferon gama (IFN-γ). These phosphorilation in serine residues determines a decreased efficacy in the trophic and metabolic pathways and, consequently, changes in the triggers for growth, replication, and development of cellular organelles 7, 12 .
Consequently, the timing systems of fetal cellular growth are changed, resulting in IUGR.
We noted a decreased intestinal and hepatic expression of IRβ, probably indicating that the insulin level is increased, leading to a downregulation of the receptor. It is known that newborns small for gestational age present low levels of circulating insulin and type 1 insulin-like growth factor (IGF-1), followed by an increase during the first years of life 13 . Our model is fetal, so the hormone levels control may still not be well defined, what could explain these results. In addition, we also observed an increased hepatic IRS-1 and a decreased intestinal IRS-1, and the lower the expression, the greater the fetal insulin resistance and IUGR. In the study of intestine-liver axis, the liver could try to compensate changes that occurred during the intestinal inflammatory process of gastroschisis, and for this reason, the liver IRS-1 increased.
A way to control the insulin resistance would be to increase the expression of IRS-2, which partially compensates the lower amount of IRS-1, allowing a regulation of glucose levels in fetal organism, so that hyperglycemia does not happen 12 Analyzing the IGF-IRβ levels, we found that it is increased in the liver and intestine of fetuses with gastroschisis, similar results were found on the IUGR model in rats 14 . In a fetal sheep model, it was also found an increased IGF-IRβ, although on skeletal muscles, suggesting that the increase is a response to low circulating hormone concentrations in fetuses with IUGR 13 .
The inflammatory process that the amniotic fluid triggers in the intestinal loops in gastroschisis can be a sufficient stimulus to activate the transcription factor NF-kappa-B and promote increased inflammation of the bowel and liver. The involvement of the gut-liver axis by activation of the NF-kappaβ, or intestinal injury affecting the liver was tested in the gastroschisis model 15 .
NF-kappaβ is a transcription factor that is involved in activation of many genes, including those related to liver cell injury, endotoxemia and oxidative stress. NF-kappaβ is a heterodimeric complex of p50 and p65 subunits that interacts with the family of inhibitors Ikappaβ. When the cells are stimulated, Ikappaβ is phosphorylated with subsequent release of NF-kappaβ.
Once released, NF-kappaβ translocates into the nucleus, where it is connected to a specific sequence in the promoter region of target genes. Among the genes activated by NF-kappaβ genes are proinflammatory cytokine genes and cytotoxic genes, and genes that participate in the prevention of apoptosis during liver regeneration.
In our study, we analyzed the inhibitory protein Ikappaβ that increase its expression in the two studied organs. We believe that this result is due to the intense inflammatory process that occurs in the bowel loops during the gastroschisis, in which the organism tries to soothe inflammation by inhibiting NF-kappaβ.
Because NF-kappaβ is increased in the studied organs, the
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intestine-liver axis tries to increase the inhibition to reduce the inflammation that occurs in gastroschisis. However, it is important to remember that, even with this increase in inhibitory proteins, is not sufficient to block NF-kappaβ action and prevent inflammation in gastroschisis.
Our results showed that gastroschisis increased the hepatic and intestinal expression of Ikappaβ which could reinforce the concept that these fetuses have fetal inflammatory response syndrome. It may be possible that the inflammatory process in the bowel consumes energy that should be directed for growth.
It appears that the signals for glucose uptake involving insulin receptors are compromised and the fetus with gastroschisis may have a transitory insulin resistance 15 .
Conclusion
The gut-liver axis has an inflammatory role in the development associated changes of the metabolic pathway of glucose which could contribute to the IUGR in fetuses affected by this disease.
